What Is the Most Affordable Weight Loss Drug?

The Short Answer: Phentermine Is the Cheapest Approved Option

Phentermine, a Schedule IV sympathomimetic amine approved by the FDA for short-term obesity treatment, costs $15 to $30 per month as a generic at Walmart, Costco, or via GoodRx discounts [1]. It has been available since 1959, which means decades of generic competition have compressed its price to commodity levels. The FDA approved phentermine for BMI <30 only in combination with other interventions, and the label specifies short-term use of 12 weeks or fewer, though off-label longer use is practiced by some clinicians [2].

Phentermine works primarily by releasing norepinephrine in the hypothalamus, suppressing appetite. In a meta-analysis of 14 randomized controlled trials, phentermine monotherapy produced a mean weight loss of 3.6 kg more than placebo over 2 to 24 weeks [3]. That is modest compared with newer GLP-1 receptor agonists, but for patients paying out of pocket, the cost-per-kilogram-lost math still favors phentermine for short-cycle use.

Side effects include elevated heart rate, insomnia, dry mouth, and a small increase in blood pressure. Phentermine is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, or a history of drug abuse [2]. Patients with any of those conditions need a different agent, which shifts the affordability calculation entirely.

The combination product phentermine/topiramate ER (Qsymia) costs $170 to $220 per month with the manufacturer's savings card. In the CONQUER trial (N=2,487), patients on the high-dose formulation (15 mg/92 mg) lost 10.2% of body weight at 56 weeks versus 1.4% on placebo [4]. That efficacy profile is meaningfully better than phentermine alone, and the monthly cost is still well below brand-name GLP-1 agents.

Off-Label Drugs That Cost Under $30 Per Month

Several generic medications prescribed off-label for weight management cost under $30 per month and have clinical evidence supporting their use [5].

Metformin is the most prescribed diabetes drug in the United States and costs $4 to $10 per month at most pharmacies under GoodRx pricing [6]. The FDA has not approved it for weight loss, but a 2020 Cochrane review of 14 trials found metformin produced a mean weight reduction of 1.1 to 2.7 kg versus placebo in non-diabetic adults with obesity, with the strongest signal in patients who are insulin resistant [7]. Doses used in weight management range from 500 mg twice daily to 2 to 000 mg per day. Gastrointestinal side effects affect roughly 20 to 30% of patients at initiation but often resolve with dose titration or by switching to the extended-release formulation [7].

Topiramate monotherapy is another low-cost off-label option. It costs $10 to $25 per month as a generic and carries an FDA indication for epilepsy and migraine prophylaxis. In the topiramate arm of the TOPIC trial, 96 mg per day produced 6.3% weight loss versus 2.6% on placebo at 6 months [8]. Cognitive side effects (word-finding difficulties, slowed processing) limit tolerability in a subset of patients, and it is teratogenic, requiring contraception counseling in women of reproductive age [9].

Bupropion alone, at $20 to $40 per month as a generic, is associated with modest weight loss of 1.3 kg over placebo in pooled data [10]. Its combination product with naltrexone (Contrave) drops to $90 to $130 per month with discount cards and showed 5.0% greater weight loss than placebo at 56 weeks in the COR-I trial (N=1,742) [11].

How Compounded GLP-1s Changed the Affordability Equation

Brand-name semaglutide (Wegovy) lists at approximately $1,349 per month without insurance. Brand-name tirzepatide (Zepbound) lists at approximately $1,059 per month at the lowest commercially available dose. For most uninsured patients, those prices are not realistic. Compounding pharmacies operating under FDA 503B outsourcing facility registration changed that math significantly [12].

During the FDA-declared shortage of semaglutide and tirzepatide (active from 2022 through early 2025 for certain dosage forms), licensed 503B facilities were permitted to compound copies of those drugs. Compounded semaglutide from a 503B pharmacy ran $200 to $400 per month depending on the dose and supplier, while compounded tirzepatide ran $300 to $500 per month. The FDA's 503B framework requires Current Good Manufacturing Practice compliance, sterility testing, and batch release testing, which distinguishes these products from non-compliant 503A retail compounders [12].

In STEP-1 (N=1,961), subcutaneous semaglutide 2.4 mg once weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% on placebo (P<0.001) [13]. That is the benchmark against which every cheaper alternative is measured. Tirzepatide's SURMOUNT-1 trial (N=2,539) showed 22.5% mean weight loss at 72 weeks on the 15 mg dose versus 2.4% on placebo [14]. No generic or off-label agent approaches those magnitudes.

The clinical trade-off is straightforward. Phentermine costs 50 to 100 times less per month than branded GLP-1 therapy but produces roughly one-sixth the weight loss. Compounded semaglutide bridges that gap: it costs about 70 to 80% less than brand Wegovy while delivering the same active molecule at the same doses used in STEP-1 [13]. A patient choosing between options is not choosing between "cheap and effective" versus "expensive and effective." They are choosing on a cost-per-percent-body-weight-lost basis, and that number favors compounded semaglutide over phentermine when the treatment duration exceeds 3 months.

FDA-Approved Weight Loss Drugs: A Cost and Efficacy Comparison

The FDA has approved seven distinct weight loss drug entities since 1959. Here is how they rank by out-of-pocket monthly cost and mean weight loss versus placebo [1][2][4][13][14][15][16].

Phentermine (generic): $15, $30/month. Mean excess weight loss: 3.6 kg at 12 weeks [3]. Short-term use only.

Orlistat 60 mg OTC (Alli): $50, $70/month. Orlistat inhibits pancreatic lipase, blocking about 30% of dietary fat absorption. In a 2-year trial, 120 mg three times daily (prescription dose) produced 3.4 kg more weight loss than placebo with associated reductions in LDL cholesterol [15]. Gastrointestinal side effects (oily stools, fecal urgency) are common and dose-dependent.

Phentermine/topiramate ER (Qsymia): $170, $220/month with coupon. 10.2% weight loss at 56 weeks in CONQUER [4].

Bupropion/naltrexone ER (Contrave): $90, $130/month with GoodRx. 5.0% greater weight loss versus placebo at 56 weeks in COR-I [11].

Naltrexone/bupropion is not available as two separate generics combined at equivalent doses, but the individual generics cost $20 to $50 per month together for patients whose prescribers are comfortable with off-label combination dosing.

Liraglutide 3.0 mg (Saxenda): $1,200, $1,350/month without insurance. In the SCALE Obesity trial (N=3,731), liraglutide 3.0 mg produced 8.4% mean weight loss versus 2.8% on placebo at 56 weeks [16]. Its daily injection schedule and cost make it a difficult sell relative to weekly semaglutide.

Semaglutide 2.4 mg (Wegovy): $1,300, $1,400/month without insurance. 14.9% mean weight loss at 68 weeks in STEP-1 [13].

Tirzepatide (Zepbound): $1,059/month for 2.5 mg starting dose, up to $1,600/month for 15 mg without insurance. 22.5% mean weight loss at 72 weeks in SURMOUNT-1 on 15 mg [14].

Insurance, Coupons, and Patient Assistance Programs

Insurance coverage for weight loss drugs remains inconsistent. Medicare Part D was prohibited from covering weight loss drugs until the Treat and Reduce Obesity Act amendments began changing that framework, and Wegovy gained limited Medicare coverage for cardiovascular risk reduction following the SELECT trial results in 2023 [17]. Medicaid coverage varies by state.

The SELECT trial (N=17,604) found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and overweight or obesity, with no history of diabetes [17]. That cardiovascular indication has become a coverage argument for insurers who previously excluded obesity drugs.

Novo Nordisk's savings program caps Wegovy at $0 per month for commercially insured patients who qualify, and at $650 per month for uninsured patients meeting income criteria. Eli Lilly's savings card reduces Zepbound to $550 per month for uninsured patients at qualifying doses [18]. Those are not trivial reductions from list price, but they still exceed what compounded alternatives cost.

The American Association of Clinical Endocrinologists 2023 obesity guidelines state: "Pharmacotherapy for obesity should be considered as an adjunct to intensive lifestyle intervention in patients with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity" [19]. That guidance does not specify which agent, meaning the prescribing decision can legitimately account for cost when efficacy differences are acceptable to the patient.

Telehealth and Membership Programs

Telehealth platforms have made GLP-1 prescriptions more accessible, though the drug cost itself still dominates the total out-of-pocket expense [20]. A typical telehealth consultation for weight management costs $100 to $200 for the initial visit and $50 to $75 per follow-up. When the prescribed drug is phentermine at $20 per month, that consultation cost is a large relative fraction of the total spend. When the drug is compounded semaglutide at $300 per month, the consultation is a minor line item.

Several direct-to-patient telehealth programs bundle the consultation and drug together at monthly prices between $250 and $500 for compounded GLP-1 products. Those prices include clinical monitoring, dose adjustment, and asynchronous provider messaging. For patients without primary care access or with high specialist copays, that bundled model may produce net savings relative to the fragmented fee-for-service alternative.

Patients should verify that any telehealth program prescribing compounded semaglutide or tirzepatide sources from an FDA-registered 503B outsourcing facility. A 2024 FDA warning letter campaign identified dozens of non-compliant compounders selling subpotent or contaminated products [12]. The 503B distinction is the minimum quality threshold a patient should require.

How to Choose Based on Your Clinical Profile

Not every affordable drug is appropriate for every patient. The right affordable drug depends on comorbidities, contraindications, and how much weight loss is clinically necessary [19].

Patients with type 2 diabetes or insulin resistance who need modest weight loss of 3 to 5% body weight may get adequate results from metformin at $4 to $10 per month, with the added benefit of glycemic control [7]. Patients without cardiovascular disease, hypertension, or glaucoma who need a short 3-month push can use phentermine at $15 to $30 per month [2][3]. Patients who need sustained loss of 10% or more body weight and can tolerate injections will get the most cost-effective outcome per kilogram lost from compounded semaglutide, even at $300 to $400 per month, given that the alternative branded agent costs more than three times as much for the same molecule [13].

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity specified that drug selection should account for "efficacy, safety, tolerability, and cost" as equally weighted factors [20]. Cost is a legitimate clinical variable, not a secondary concern.

Patients with a BMI <27 do not meet FDA criteria for any approved weight loss pharmacotherapy. Lifestyle intervention remains the first-line treatment for that group, and no drug is appropriate or affordable if it is not clinically indicated [19].

What the Evidence Says About Long-Term Affordability

Weight regain after stopping GLP-1 therapy is substantial. The STEP-4 trial showed that patients who discontinued semaglutide after 20 weeks regained two-thirds of their lost weight within 48 weeks of stopping [21]. That finding has direct financial implications. A drug that requires indefinite use to maintain results has a different lifetime cost than a short-course drug.

Phentermine's label restricts use to 12 weeks, and evidence for sustained weight maintenance after stopping is absent [2]. Orlistat can be used long-term, and a 4-year trial showed sustained weight loss maintenance of 2.8 kg above placebo, with reduced progression to type 2 diabetes by 37.3% [15]. That long-term diabetes prevention effect carries its own downstream cost-offset value.

A 2021 analysis published in Diabetes Care estimated that the cost per quality-adjusted life year (QALY) for semaglutide 2.4 mg was approximately $175,000 using US list prices, which exceeds the conventional $100,000 to $150,000 willingness-to-pay threshold. At compounded semaglutide prices, that QALY estimate drops to approximately $40,000 to $60,000, placing it within the range of other commonly reimbursed medications [22].

Patients who achieve significant weight loss, particularly those reducing BMI below 35, may reduce spending on comorbidity medications for hypertension, dyslipidemia, sleep apnea therapy, and diabetes management. A 10% body weight reduction reduces systolic blood pressure by approximately 6 to 10 mmHg in hypertensive patients with obesity, potentially eliminating the need for one antihypertensive agent [23]. Those savings compound over time.

Practical Steps for Accessing the Most Affordable Option

Access is as important as price. Phentermine requires a Schedule IV prescription, which some states restrict to in-person visits. Check your state's telemedicine prescribing rules before booking a virtual appointment expecting to receive phentermine [2].

Metformin requires a prescription but faces no controlled substance restrictions. Any telehealth platform or primary care provider can prescribe it in a single visit [6]. Generic orlistat (Alli 60 mg) is available over the counter at most pharmacies without a prescription, making it the most accessible option even if not the cheapest [15].

For compounded semaglutide or tirzepatide, the supply chain matters. Confirm the pharmacy holds FDA 503B registration. Ask for a certificate of analysis (COA) confirming the batch potency and sterility test results before starting a new supply [12]. Those documents should be provided on request without hesitation by any legitimate 503B facility.

The Obesity Medicine Association recommends that clinicians document a weight management plan that includes both pharmacological and behavioral components, noting that drug therapy alone without dietary and physical activity counseling produces inferior results compared with combined approaches at every price point [24]. A $15 phentermine prescription without behavioral support produces less weight loss than the same drug combined with structured dietary counseling [3].

Start with the most affordable agent that matches your clinical profile. If that agent produces insufficient results at 12 to 16 weeks, escalate to the next cost tier rather than starting at the top. Most clinical guidelines support a stepwise approach to weight management pharmacotherapy [19][20].